Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31,973 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial.
Jin S, Zhao R, Zhou C, Zhong Q, Shi J, Su C, Li Q, Su X, Chi H, Lu X, Jiang G, Chen R, Han J, Jiang M, Qiao S, Liu J, Song M, Song L, Du Y, Chang Z, Wang M, Dong M, Zhong Y, Yu P, Zhang X, Zong H. Jin S, et al. Among authors: han j. Int J Cancer. 2023 Apr 15;152(8):1648-1658. doi: 10.1002/ijc.34372. Epub 2022 Dec 1. Int J Cancer. 2023. PMID: 36444498 Clinical Trial.
Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers.
Tao Z, Liu J, Li T, Xu H, Chen K, Zhang J, Zhou H, Sun J, Han J, Guo Z, Yang H, Cao WM, Hu X. Tao Z, et al. Among authors: han j. Front Oncol. 2021 Sep 28;11:741142. doi: 10.3389/fonc.2021.741142. eCollection 2021. Front Oncol. 2021. PMID: 34650924 Free PMC article.
31,973 results
You have reached the last available page of results. Please see the User Guide for more information.